安圖生物(603658.SH):控股股東擬增持1.5億元-3億元公司股份 已增持128.46萬股
格隆匯8月21日丨安圖生物(603658.SH)公佈,2024年8月21日,鄭州安圖生物工程股份有限公司控股股東鄭州安圖實業集團股份有限公司(以下簡稱“安圖實業”)通過上海證券交易所繫統以集中競價交易方式增持公司128.46萬股(以下簡稱“首次增持”),佔公司總股本的0.22%,本次增持成交總金額5004.008萬元(不含交易費)。
基於對公司未來發展前景的信心及對公司價值的認可,同時為切實維護廣大投資者權益,增強投資者信心,安圖實業計劃自首次增持之日(2024年8月21日)起6個月內,以其自有資金通過上海證券交易所繫統以集中競價交易方式擇機增持公司股份,擬增持股份金額不低於人民幣1.5億元且不超過人民幣3億元(含本次已增持股份金額)。後續增持計劃不設價格區間,將根據公司股票價格波動情況及資本市場整體趨勢實施增持計劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.